Doriano Fabbro, PhD in Biology, has 25 years of experience in drug discovery in Pharma (Ciba-Geigy, Novartis) as well as Biotech (Piqur Therapeutics) following 10 years in academia. He has led the NIBR Expertise Platform Kinases dedicated to global Kinase Drug Discovery Projects for several Oncology, Immunology, Inflammation, Respiratory Disease, Muscular Disease and Cardiovascular.
Since 2012 he is Chief Scientific Officer of Piqur Therapeutics (Basel Switzerland), a small company devoted to the discovery of PI3K/mTOR inhibitors as well as scientific advisor for several pharmaceutical companies in the area of kinase drug discovery.
During his career he contributed to the development of the following approved anticancer drugs Glivec® (Imatinib, BcrABL inhibitor), Tasigna® (Nilotinib, BcrAbl inhibitor), Afinitor® (Everolimus, mTOR inhibitor), Rydapt® (Midostaurin, Kit and Flt-3 inhibitor). In addition he contributed to the development of Apelisib (PI3K inhibitor), Buparlisip (PI3K inhibitor), Vatalinib (VEGFR inhibitor, Luminespib (hsp90 inhibitor) and many more.